



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/063,661	05/07/2002	Audrey Goddard	P3230R1C001-168	6201
30313	7590	02/23/2006	EXAMINER	
KNOBBE, MARTENS, OLSON & BEAR, LLP			SEHARASEYON, JEGATHEESAN	
2040 MAIN STREET			ART UNIT	PAPER NUMBER
IRVINE, CA 92614			1647	

DATE MAILED: 02/23/2006

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES PATENT AND TRADEMARK OFFICE

---

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

**MAILED**  
**FEB 23 2006**  
**GROUP 1600**

**BEFORE THE BOARD OF PATENT APPEALS  
AND INTERFERENCES**

Application Number: 10/063,661  
Filing Date: May 07, 2002  
Appellant(s): GODDARD ET AL.

---

Anne Marie Kaiser  
For Appellant

**EXAMINER'S ANSWER**

This is in response to the appeal brief filed 11/21/2005 appealing from the Office action mailed 6/22/2005.

**(1) Real Party in Interest**

A statement identifying the real party in interest is contained in the brief.

**(2) Related Appeals and Interferences**

A statement identifying the related appeals and interferences which will directly affect or be directly affected by or have a bearing on the decision in the pending appeal is contained in the brief.

**(3) Status of Claims**

The statement of the status of the claims contained in the brief is correct.

**(4) Status of Amendments**

The appellant's statement of the status of amendments after final rejection contained in the brief is correct.

**(5) Summary of Claimed Subject Matter**

The summary of claimed subject matter contained in the brief is essentially correct.

**(6) Grounds of Rejection to be Reviewed on Appeal**

The appellant's statement of the grounds of rejection to be reviewed on appeal in the brief is correct. The changes are as follows:

**Withdrawn Rejections**

The following grounds of rejection are not presented for review on appeal because the examiner has withdrawn them.

The rejection of claims of claims 6 and 11-13 for lacking enablement commensurate in scope under 35 U.S.C. § 112, first paragraph.

Art Unit: 1647

The rejection of claims of claims 6 and 12-13 for as containing subject matter that was not described (written description) in the specification under 35 U.S.C. § 112, first paragraph.

**(7) Claims Appealed**

The copy of the appealed claims contained in the Appendix to the brief is correct.

**(8) Prior Art of Record**

Hu et al., Analysis of genomic and proteomic data using advanced literature mining. Journal of Proteome Research, Vol. 2, pp. 405-412 (2003).

Haynes et al., Proteome analysis: biological assay or data archive? Electrophoresis, Vol. 19(11), pp. 1862-1871 (1998).

Chen et al., Discordant protein and mRNA expression in lung adenocarcinomas. Mol. and Cell. Proteomics, Vol. 1, pp. 303-313 (2002).

Gygi et al., Correlation between protein and mRNA abundance in yeast. Mol. Cell. Biol., Vol. 19(4), pp. 1720-1730 (1999).

Bruce Alberts et al., Molecular Biology of the Cell, 3<sup>rd</sup> ed. (1994).

Bruce Alberts et al., Molecular Biology of the Cell, 4<sup>th</sup> ed. (2002).

Benjamin Lewin., Regulation of transcription. Genes VI, Chapter 29, pp. 847-848 (1997).

Zhigang et al., Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. World Journal of Surgical Oncology, Vol. 2(13), pp. 1-7 (2004).

Meric et al., Translation initiation in cancer: A Novel target for therapy. Cancer Therapeutics., Vol. 1, pp. 971-979 (2002).

**(9) Grounds of Rejection**

The following ground(s) of rejection are applicable to the appealed claims:

**Claim Rejections—35 U.S.C. § 101**

(i). 35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

(ii). Claims 6-8 and 11-17 are drawn to an isolated polypeptide having SEQ ID NO: 136 (PRO1926 polypeptide). The claimed invention is not supported by either a specific and substantial asserted utility or a well-established utility. A specific and substantial utility is one that is particular to the subject matter claimed and that identifies a “real world” context of use for the claimed invention, which does not require further research.

The specification discloses the polypeptide of SEQ ID NO: 136 (or PRO1926), the nucleic acid of SEQ ID NO: 135 encoding the polypeptide, and antibodies against the polypeptide. The specification does not disclose that PRO1926 has significant structural similarity to any fully characterized protein. There is no biological activity, expression pattern, phenotype, disease or condition, ligand binding partner, or any other specific feature that is disclosed as being associated with PRO1926. Without any information as to the specific properties of PRO1926, the mere identification of such as

Art Unit: 1647

being a membrane-bound polypeptide possessing several transmembrane domains is not sufficient to impart a well-established utility to the claimed polypeptides. The instant disclosure fails to provide any significant information or evidence on the specific biological functions or physiological significance of PRO1926 of the present invention and fails to disclose a patentable utility for the claimed invention.

First, the invention lacks a well-established utility. A well-established utility is a specific, substantial, and creditable utility that is well known, immediately apparent, or implied by the specification's disclosure of the properties of a material. The sequence and prior art search does not reveal that the polypeptide of SEQ ID NO: 136, the nucleic acid encoding the polypeptide or an antibody that binds to the polypeptide has any well-established biological functions or any physiological significance. No art of record discloses or suggests any property or activity for the claimed molecules such that another non-asserted utility would be well-established for the claimed invention.

Secondly, the present invention does not disclose a specific and substantial utility. Example 18, of the instant application discloses cDNA amplification of molecule (DNA82340-2530) that is more highly expressed in normal esophagus tissue compared to esophageal tumor. Thus, it is asserted the PRO1926 polypeptide encoded by the mRNA is also more highly expressed in normal esophagus tissue compared to esophageal tumor. The specification further asserts that the polypeptide of the present invention is useful not only as a diagnostic marker for the presence of one or more cancerous tumors, but also serves as a therapeutic target for the tumor treatment (pages 100 and 140). The Examiner notes that the PCR amplification described in

Example 18 merely measures the mRNA level; it does not measure the over-expression of the polypeptide of SEQ ID NO: 136. There is no sufficient information or experimental data presented on whether the PRO1926 polypeptide of the present invention can serve as a reliable diagnostic marker for esophageal tumors; there is no statistical analysis of the expression data. Moreover, the assay does not establish a causative link between the polypeptide (or nucleic acid) of the present invention and esophageal tumors.

Without such critical information, one skilled in the art would not be able to use the molecule of the present invention as a diagnostic marker or as a therapeutic target for treatment of esophageal tumors without undue experimentation. Accordingly, the results obtained based upon the assay described in Example 18 only serve as the beginning point for further research on the biological functions or physiological significance of the antibody that binds to the polypeptide of SEQ ID NO: 136 or polypeptide of SEQ ID NO: 136 or the nucleic acid encoding the polypeptide, and does not provide a specific and substantial utility for the present invention.

The specification also asserts that the nucleic acid sequences of the present invention may be used in gene therapy (the middle of page 91), the polypeptide may be employed as a therapeutic agent (the middle of page 93), and that the polypeptide of the present invention may be used in diagnostic assays (page 112). These asserted utilities are not specific and substantial because they do not identify or reasonably confirm a "real world" context of use. The specification fails to disclose the biological functions of the claimed polypeptides and any specific diseases that are associated with or can be treated with the claimed molecules. The data do not support the

Art Unit: 1647

specification's assertion that PRO1926 polypeptides can be used as cancer diagnostic agents. Significant further research would have been required of the skilled artisan to reasonably confirm that PRO1926 polypeptide is more highly expressed in normal esophagus tissue compared to esophageal tumor, can be used as a cancer diagnostic agent; and thus the asserted utility is not substantial. In the absence of information regarding whether or not PRO1926 polypeptide levels are also different between specific normal and cancerous tissues, the proposed use of the polypeptide of PRO1926 (SEQ ID NO: 136) as diagnostic markers and therapeutic targets are simply starting points for further research and investigation into potential practical uses of the polypeptides. See *Brenner v. Manson*, 383 U.S. 519, 148 USPQ 689 (Sup. Ct. 1966), wherein the court held that:

"The basic quid pro quo contemplated by the Constitution and the Congress for granting a patent monopoly is the benefit derived by the public from an invention with substantial utility", "[u]nless and until a process is refined and developed to this point-where specific benefit exists in currently available form-there is insufficient justification for permitting an Appellant to engross what may prove to be a broad field", and "a patent is not a hunting license", "[i]t is not a reward for the search, but compensation for its successful conclusion."

In summary, all the asserted uses of the claimed invention are simply starting points for further research and investigation into potential practical uses of the claimed polypeptide of PRO1926. "Congress intended that no patent be granted on a chemical compound whose sole 'utility' consists of its potential role as an object of use-testing." *Brenner v. Manson*, 148 USPQ at 696.

#### **Claim Rejections—35 U.S.C. § 112, First Paragraph, Enablement**

(iii) The following is a quotation of the first paragraph of 35 U.S.C. 112:



Art Unit: 1647

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

(iv) Claims 6-8 and 11-17 are also rejected under 35 U.S.C. 112, first paragraph.

Specifically, since the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

Further, *even if* the specification taught how to use the PRO1926 polypeptide, enablement would not be commensurate in scope with claims 14-17, which encompass % variants of SEQ ID NO: 130 (claims 14 and 15, for example), and fragments of SEQ ID NO: 130 (claims 14 and 15 for example). However, even if the claimed invention is eventually deemed to have a credible, specific and substantial asserted utility or a well-established utility, claims 14-17 would remain rejected under 35 U.S.C. § 112, first paragraph.

The specification discloses one PRO1926 amino acid sequence with particularity. No other PRO1926 variants or fragments comprising the sequence meeting the limitations of these claims were ever identified or particularly described. The specification does not teach how to make PRO1926 variants or fragments comprising the sequence. Since a biological function of PRO1926 is not clear, and since one skilled in the art could not determine with reasonable expectation of success what a biological function of PRO1926 would be, the skilled artisan would not be able to make PRO1926 variants or fragments comprising the sequence, and test them for biological activity.

Art Unit: 1647

Furthermore, the specification provides no guidance as to how the skilled artisan could use PRO1926 variant or fragment, as no functional limitation associated with PRO1926 variants or fragments comprising the sequence have been described in the specification.

The problem of predicting protein structure from sequence data and in turn utilizing predicted structural determinations to ascertain functional aspects of the protein is extremely complex. While it is known that many amino acid substitutions are generally possible in any given protein, the positions within the protein's sequence where such amino acid substitutions can be made with a reasonable expectation of success are limited. Certain positions in the sequence are critical to the protein's structure/function relationship, e.g. such as various sites or regions directly involved in binding activity and in providing the correct three-dimensional spatial orientation of binding and active sites. However, Applicant has provided little or no guidance beyond the mere presentation of sequence data to enable one of ordinary skill in the art to determine, without undue experimentation, the positions in the protein which are tolerant to change (e.g. such as by amino acid substitutions or deletions), and the nature and extent of changes that can be made in these positions. Therefore, undue experimentation would be required of the skilled artisan to make and/or use the claimed invention in its full scope, because the skilled artisan would have no reasonable expectation of being able to make and use PRO1926 variants or fragments comprising the sequence for any purpose stated in the specification.

Due to the large quantity of experimentation necessary to generate the infinite number of derivatives recited in the claims and possibly screen same for activity, the lack of direction/guidance presented in the specification regarding which structural features are required in order to provide activity, the absence of working examples directed to same, the complex nature of the invention, the state of the prior art which establishes the unpredictability of the effects of mutation on protein structure and function, and the breadth of the claims which fail to recite any structural or functional limitations, undue experimentation would be required of the skilled artisan to make and/or use the claimed invention in its full scope.

**Claim Rejections—35 U.S.C. § 112, First Paragraph, (Written Description)**

(v) Claims 14-17 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Specifically, claims 14-17 are directed to an isolated polypeptide having at least 95%, and 99% amino acid sequence identity to (a) the amino acid sequence of the polypeptide of SEQ ID NO: 136, (b) the amino acid sequence of the polypeptide of SEQ ID NO: 136, lacking its associated signal peptide, or (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203547; wherein the polypeptide or a fragment thereof can be used to generate an antibody which can be used to specifically detect the polypeptide of

Art Unit: 1647

SEQ ID NO: 136 in stomach or lung tissue samples. The claims also recite a chimeric polypeptide comprising a polypeptide fused to a heterologous polypeptide.

To provide evidence of possession of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of complete or partial structure, physical and/or chemical properties, functional characteristics, structure/function correlation, methods of making the claimed product, or any combination thereof.

The claims are drawn to polypeptides having at least 95% or 99% sequence identity with a particular disclosed sequence. The claims do not require that the claimed polypeptide possess any particular biological activity, nor any particular conserved structure, or other disclosed distinguishing feature. The specification teaches that PRO1926 has (unspecified) homology to secreted and transmembrane polypeptides. The structure of the putative PRO1926 peptide is briefly discussed in Figure 136, as having a putative signal sequence, corresponding to amino acids 1-23 and a putative transmembrane domain around amino acids 161-182. Putative N-glycosylation site around amino acids 184-187 is identified. It also contends putative glycosaminoglycan attachment site is around amino acids 37-40 and 236-239. camp and cGMP-dependent protein kinase phosphorylation site is identified around amino acids 151-154. It also contends N-myristoylation sites are around amino acids 33-38, 36-41, 38-44 and 229-234. Further it is described that there is a putative amidation site around amino acids 238-241. Finally, Applicants also describe a putative ATP/GTP-binding site motif A (P-loop). However, there is no functional characteristic associated with these motifs

(domains), hence the mere observation that they exist is not probative of function or utility. Further, there is no disclosure that the protein is expected to be a transmembrane protein, nor of any extracellular domain.

*Vas-Cath Inc. v. Mahurkar*, 19USPQ2d 1111, clearly states that “Appellant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of *the invention*. The invention is, for purposes of the ‘written description’ inquiry, *whatever is now claimed*” (See page 1117). The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed” (See *Vas-Cath* at page 1116).

With the exception of the sequences referred to above, the skilled artisan cannot envision the detailed chemical structure of the encompassed polypeptides, and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of isolating it. The polypeptide itself is required. See *Fiers v. Revel*, 25 USPQ2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1016.

One cannot describe what one has not conceived. See *Fiddes v. Baird*, 30 USPQ2d 1481 at 1483. In *Fiddes*, claims directed to mammalian FGF’s were found to be unpatentable due to lack of written description for that broad class. The specification provided only the bovine sequence.

Therefore, only an isolated polypeptide consisting of the amino acid sequence of SEQ ID NO: 1925, but not the full breadth of the claim meets the written description provision of 35 U.S.C. §112, first paragraph. Appellant is reminded that *Vas-Cath* makes clear that the written description provision of 35 U.S.C. §112 is severable from its enablement provision (see page 1115).

**Claim Rejections—35 U.S.C. § 102 (b)**

(vi). The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(vii). Claims 6-8, and 11-17 are rejected under 35 U.S.C. 102(b) as being anticipated by Valenzuela et al. (WO 00/55375, September 2000).

Appellants contend that they are entitled to an earlier priority date that is earlier than that of Valenzuela et al. based on the disclosure of SEQ ID NO: 135 and 136 and the data of Example 18 (differential tissue cDNA expression in tumor versus normal tissue), that was disclosed in PCT Application PCT/US00/23328, filed 8/24/2000 (see Brief page 7). However, Appellants have not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 120. Although, the previous patent application discloses the same polypeptide (SEQ ID NO: 136) sequence and polynucleotides (SEQ ID NO: 135) encoding the polypeptide as the instant specification, the disclosure is not enabling for the instant invention directed to the polypeptides and

Art Unit: 1647

because the disclosed function (differential cDNA) expression does not impart utility to the instant invention directed the polypeptide for the reasons set forth below and the previous Office Actions dated 1/11/05 and 6/22/05. Therefore, the filing date of 7 May 2002 is maintained as the priority date.

Valenzuela et al., (WO 00/55375, September 2000) disclose an amino acid sequence that has 100% overall identity to SEQ ID NO: 136 of the instant invention. It meets the limitations of claims 6-8, 11, 14 and 15. It also describes fusion proteins with heterologous polypeptide such as maltose binding proteins (page 280, lines 25-30). In addition, the reference also teaches epitope tagging of the protein (page 280, lines 30-31), meeting the limitations of claims 12, 13, 16 and 17. Therefore, instant claims 6-8 and 11-17 remain rejected under 35 U.S.C. 102(b) as being anticipated over Valenzuela et al. (2000).

**Nature of the invention and the state of the prior art.** The present invention is drawn to an antibody that binds to the polypeptide of SEQ ID NO: 136, which polypeptide does not have any defined biological functions or activities. The specification merely lists (Example 18 of page 145) that the mRNA of SEQ ID NO: 135 is more highly expressed in normal esophagus tissue compared to esophageal tumor in the assay described in Example 18. There is insufficient information, as noted above in the utility rejection section, to enable the skilled artisan to use the claimed polypeptide absent undue experimentation. Even if the mRNA of SEQ ID NO: 135 that encodes the polypeptide of SEQ ID NO: 136 were more highly expressed in normal esophagus tissue compared to

Art Unit: 1647

esophageal tumor, the polypeptide of SEQ ID NO: 136 would not necessarily be more highly expressed in normal esophagus tissues because there is no correlative link established between the mRNA expression and the level of the polypeptide. The prior art teaches that the multi-level control of protein synthesis and degradation in cells and tissues means that only the direct analysis of mature protein products can reveal their correct identities, their relevant state of modification and/or association and their amounts (see, e.g., Haynes et al., Electrophoresis 19: 1862-1871, 1998, bottom of left column of page 1870). Haynes et al., who studied more than 80 polypeptides relatively homogeneous in half-life and expression level found no strong correlation between polypeptide and transcript levels. For some genes, equivalent mRNA levels translated into polypeptide abundances, which varied more than 50-fold. That is polypeptide levels cannot be accurately predicted from mRNA levels (page 1863, second paragraph and Figure 1). The literature also cautions researchers against drawing conclusions based on small changes in transcript expression levels between normal and cancerous tissue. Hu et al., analyzed 2286 genes that showed a greater than 1 –fold difference in mean expression level between breast cancer samples and normal samples in a microarray (see, Journal of Proteome Research 2: 405-412, 2003, middle right hand column of page 408). Hu et al. discovered that, for genes displaying a 5–fold change or less in tumors compared to normal, there was no evidence of correlation between altered gene expression and a known role in the disease. However, among genes with a 10-fold or more change in expression level, there was a strong and significant correlation between expression level and a published role in the disease (see discussion section). Even if



increased mRNA levels could be established for PRO1926, it does not follow that polypeptide levels would also be amplified.

Chen et al. (Molecular and Cellular Proteomics 1: 304-313, 2002) disclose that twenty-eight of the 165 protein spots (17%) or 21 of 98 genes (21.4%) had a statistically significant correlation between protein and mRNA expression (abstract). In addition, it is stated that no significant correlation between mRNA and protein expression was found ( $r=-0.025$ ) if the average levels of mRNA or protein among all samples were applied across the 165 protein spots (98 genes): The reference also teaches that the mRNA/protein correlation coefficient also varied among proteins with multiple isoforms, indicating potentially separate isoform-specific mechanisms for the regulation of protein abundance. Chen et al. clearly state “the use of mRNA expression patterns by themselves, however, is insufficient for understanding the expression of protein products” (see page 304). In a study using a quantitative analysis of mRNA and protein expression within the same lung adenocarcinomas, it was shown that only a subset of the proteins exhibited a significant correlation with mRNA abundance.

#### **(10) Response to Argument**

I. Rejection of claims 6-8 and 11-17 under the utility requirement of 35 USC §101.

At the middle of page 8 of the Brief, Appellants argue that the asserted patentable utility of PRO1926 polypeptide is based on the disclosure in Example 18 of the instant application that the mRNA encoding the PRO1926 polypeptide is more highly expressed normal stomach or normal lung compared to stomach tumor or lung

tumor. From the page 8 to the top of page 10 of the Brief, Appellant, citing case law and MPEP, reviews the legal standard for utility, with which the Examiner takes no issue.

Beginning at page 10 of the Brief, Appellants argue the differential expression of PRO1926 mRNA was detected using well-established technique of quantitative PCR amplification of cDNA libraries isolated from different human normal and tumor tissues samples. To ensure that equivalent amounts of nucleic acid were used in each reaction, the cDNA for  $\beta$ -actin was used as a control. Appellants argue that identification of the differential expression of a PRO polypeptide-encoding mRNA in one or more tumor tissues as compared to one or more normal tissues of the same tissue type “renders the molecule useful diagnostically before the determination of the presence or absence of tumor in a subject suspected of possessing a tumor.” It is further asserted that because it is well established that changes in mRNA levels lead to changes in the level of the encoded protein, one would expect the PRO1926 protein to be differentially expressed in normal esophagus compared to esophageal tumor. Appellants argue that PRO1926 polypeptides may be used in diagnostic assays for PRO1926 (polypeptide), e.g., detecting its expression (and in some cases, differential expression) in specific cells, tissues or serum. Various diagnostic assay techniques known in the art may be used, such as competitive binding assays, direct or indirect sandwich assays and immunoprecipitation assays conducted in either heterogeneous or homogeneous phases. Appellants assert that taken together, the specification clearly discloses the “real world” use of the claimed polypeptide as diagnostic tools for cancer, particularly esophageal tumors.

In page 12 of the brief, Appellants argue that during the course of the prosecution, the Examiner had made several irrelevant arguments regarding gene amplification and an increase in gene expression, as well as the role of aneuploidy in cancer, using Sen and Pennica et al references. However, as conceded by the Appellants the Examiner did indicate in the Final Office Action mailed 6/22/2005 that Example 18 did measure mRNA levels in the tumor and normal controls. Thus, Sen and Pennica et al references were considered no longer relevant. It is also noted that the Examiner had previously incorrectly indicated that the expression was based on microarray experiments. However, Example 18 expression was based on PCR analysis of cDNA libraries.

Appellant's arguments have been fully considered, but are not deemed to be persuasive for the following reasons. An assay using PCR amplification as described in Example 18, the Appellants merely measures the mRNA level; it does not measure the over-expression of the polypeptide of SEQ ID NO: 136. There is no evidence regarding whether the PRO1926 polypeptide of SEQ ID NO: 136 is more highly expressed in normal esophagus compared esophageal tumor tissues. There is no sufficient information or experimental data presented on whether the polypeptide (SEQ ID NO: 136) of the present invention can serve as a reliable diagnostic marker for esophageal tumor. Moreover, the assay does not establish a causative link between the polypeptide of the present invention and esophageal tumor. Without such critical information, one skilled in the art would not be able to use the polypeptide of the present invention as a therapeutic target for treatment of esophageal tumor without undue experimentation.

The information disclosed in the instant specification is preliminary at best. Finally, art indicates that the changes in mRNA expression do not correlate with polypeptide levels (Hu et al., Haynes et al., Chen et al. and Gygi et al). Clearly further research would be required to determine whether the PRO1926 polypeptide can serve as a reliable diagnostic marker for esophageal tumors or as a therapeutic target for treatment of stomach or lung tumors. Accordingly the claimed utility is not substantial.

Appellants assert that to establish a *prima facie* showing that the claimed subject matter lacks utility, the Examiner must "provide evidence showing that one of ordinary skill in the art would reasonably doubt the asserted utility" (see page 14 of the brief). Appellants claim that the Examiner has issued first Office Action and final Office Action, during the prosecution of the instant application. In addition, it is asserted that none of these papers provide any evidence that one of ordinary skill in the art would reasonably doubt the asserted utility. Appellants assert that with the exception of the Hu et al., Haynes et al., Chen et al., and Gygi et al. references, the Examiner's assertions are not supported by any facts, evidence, or reasoning. The Examiner did provide Hu et al., Haynes et al., Chen et al. and Gygi et al. references in the Final Office Action dated 6/22/05 (discussed in page 6 of the Office Action) to argue that there was no significant correlation between mRNA expression and corresponding polypeptide-expression.

The Appellants assert that the Examiner states that the specification discloses that the PRO1926 polynucleotide is more highly expressed in normal esophagus tissue compared to esophageal tumor tissue, and that Appellants have asserted the use of the molecule for diagnosis (page 13 of the Brief). Further it is asserted the Examiner has

Art Unit: 1647

rejected this utility, stating that "there is no supporting evidence to indicate that the polypeptide encoded by the polynucleotide of the instant invention is also differentially expressed in the various normal and tumor tissues and as such one of skill in the art would conclude that it is not supported by a substantial asserted utility or well-established utility" (Final Office Action at page 4).

The Examiner initially rejected this utility because of the insufficiency of data presented in Example 18. The Examiner argued that there is no supporting evidence to indicate that the polypeptide encoded by the polynucleotide of the instant invention is also differentially expressed in normal tissues compared to their tumor tissue counterparts, and as such one of skilled in the art would conclude that it is not supported by a substantial asserted utility or a well-established utility. Although, the specification claims that the polynucleotide is more highly expressed in normal esophagus tissue compared to esophageal tumor, the specification does not teach what is the normal level of expression, does not indicate how high the expression level is compared to, for example, esophageal tumor; and does not provide a statistical correlation to the level of expression (for example, there is no indication of how many samples were compared to study the expression). Furthermore, even if the tumor is malignant, the specification fails to describe the type or kind of tumor present in esophageal tissues. Without knowing the identity of the esophageal tumor, one of skill in art cannot use the polypeptides for diagnosis or therapeutic purposes as asserted. The specification does not disclose a correlation between any specific disorder and the altered level or form of the claimed polypeptides. Also, the specification does not predict

whether the polypeptides would have high or low expression in a specific, diseased tissue (esophageal tumor) compared to the healthy tissue control. In addition, the specification does not teach or describe the function of this yet to be identified polypeptide (see pages 5-6 of the Examiner Action mailed 1/11/2005). Hu et al., (2003), cautions researchers from drawing conclusions based on small changes in transcript expression levels between normal and cancerous tissue (see pages 6 and 9 of the Examiner Action mailed 6/22/2005).

Secondly, the Examiner argued, "polypeptide levels cannot be accurately predicted from mRNA levels" (Haynes et al. (1998), Gygi et al. (1999) and Chen et al. (2002)). See Examiner Action mailed 6/22/2005 pages 5-6, 11 and 14 -16. Thus, the Examiner concluded that "further research needs to be done to determine whether the decrease or increase in PRO1926 cDNA expression compared to normal esophagus tissues supports a role for the peptide in the cancerous tissue; such a role has not been suggested by the instant disclosure" (page 5 of the Examiner Action mailed 6/22/2005). The Appellants assert that based on the above arguments, the Examiner has not established a *prima facie* case lacking utility for claims 6-8 and 11-17 directed to the polypeptides (page 14 of the brief). Appellants also assert that with the exception of Hu et al., Haynes et al., Gygi et al., and Chen et al. references, the Examiner's assertions are not supported by any facts, evidence or reasoning (Brief page 15). It is further argued that these references do not support the Examiner's position. Appellants thus conclude that there is simply no evidence on the record to support the Examiner's assertion that the asserted utility is not substantial, and that the invention is incomplete.

From page 14 to 19 of the Brief, Appellants refer to the declaration of Mr. Grimaldi filed under 37 CFR 1.132 (20 April 2005) and argue against the Hu et al. reference. Appellants quote from paragraphs 6 and 7 of the declaration stating that “semi-quantitative analysis employed to generate the data of example 18 is sufficient to determine if a gene is over or under expressed in tumor cells compared to corresponding normal tissue”. Further it asserted by Mr. Grimaldi that any visually detectable difference seen between two samples is indicative of at least a two-fold difference in cDNA between the tumor tissue and the counterpart normal tissue. Mr. Grimaldi also asserted that, if a difference is detected, this indicates that the gene and its corresponding polypeptide are useful for diagnostic purposes, i.e., to screen samples to differentiate between normal and tumor”. It is further asserted that PTO’s assertions are contradicted by Mr. Grimaldi’s statement, “the precise levels of gene expression are irrelevant; what matters is that there is a relative difference in expression between normal tissue and tumor tissue.” Appellants assert that this declaration makes clear that since it is the relative level of expression between normal tissue and suspected cancerous tissue that is important, how high the level of expression is in normal tissue is irrelevant (see top of page 16). Further, Appellants argue that Mr. Grimaldi states that if a difference is detected using these techniques, “this indicates that gene and its corresponding polypeptide are useful for diagnostic purposes.” Thus, Appellants contend that it is the uncontested opinion of an expert in the field that the results are reliable enough to indicate that the claimed polypeptides are useful as diagnostic tools. This has been fully considered but is not found to be persuasive. It is also noted that the

Art Unit: 1647

expert has interest in the outcome of the case, since Mr. Grimaldi is listed as an inventor and is employed by the assignee.

In assessing the weight to be given expert testimony, the examiner may properly consider, among other things, the nature of the fact sought to be established, the strength of any opposing evidence, the interest of the expert in the outcome of the case, and the presence or absence of factual support for the expert's opinion. See Ex parte Simpson, 61 USPQ2d 1009 (BPAI 2001), Cf. Redac Int'l. Ltd. v. Lotus Development Corp., 81 F.3d 1576, 38 USPQ2d 1665 (Fed. Cir. 1996), Paragon Podiatry Lab., Inc. v. KLM Lab., Inc., 948 F.2d 1182, 25 USPQ2d 1561, (Fed. Cir. 1993). In the instant situation, the nature of the fact sought to be established is whether or not a approximately 2-fold amplification of the message amplification (as suggested by the declaration) encoding PRO1926 is significant. However the literature cautions researchers from drawing conclusions based on small changes in transcript expression levels between normal and cancerous tissue. For example, as discussed above, Hu et al. (2003, Journal of Proteome Research 2:405-412) analyzed 2286 genes that showed a greater than 1-fold difference in mean expression level between breast cancer samples and normal samples in a microarray (p. 408, middle of right column) and discovered that, for genes displaying a 5-fold change or less in tumors compared to normal, there was no evidence of a correlation between altered gene expression and a known role in the disease. However, among genes with a 10-fold or more change in expression level, there was a strong and significant correlation between expression level and a published role in the disease (see discussion section). The specification fails



Art Unit: 1647

to disclose any specific “fold amplification” that is required between normal and cancerous tissue for a diagnostic determination. Is a 1-fold, a 5-fold, a 10-fold, or a 100-fold difference required? If the “fold amplification” were disclosed in the specification to be 100-fold, for example, then the cDNA that encodes the PRO1926 polypeptide would likely have a specific and substantial utility as a diagnostic marker for esophageal tumors. However, such is not the case here. Most importantly, an assay using cDNA analysis as described in Example 18 merely measures the mRNA level; it does not measure the over-expression of the polypeptide of SEQ ID NO: 136.

Beginning at the bottom of page 16 of the Brief, Appellants criticize the publication of Hu et al. and claim that Hu et al. observations are due to the “bias in the literature” toward the more prevalent ER-positive tumors as the explanation for the lack of any correlation between number of publications and gene expression levels in less-prevalent (and, therefore, less studied) ER-negative tumors, citing a statement from the article (3rd paragraph of left column of page 412) as evidence. Thus, it is the contention of the Appellants that because of this intrinsic bias, Hu’s methodology is unlikely to ever note a correlation of a disease with less differentially expressed genes and their corresponding proteins, regardless of whether or not an actual relationship between the disease and less differentially expressed gene exists. Further, Appellants argue that Hu et al. do not say that a correlation in their study means that genes with less than five-fold change in level of expression in cancer cannot serve as a molecular marker of cancer. Appellants’ argument has been fully considered, but is not deemed to be persuasive for the following reasons. Hu et al. teach that their study has two

Art Unit: 1647

implications. First, a careful hunt for corroborating evidence of a role in breast cancer should precede any further study of genes with less than 5-fold expression level change. Second, any genes with 10-fold change or more are likely to be related to breast cancer and warrant attention (2<sup>nd</sup> paragraph of left column of page 412). Hu et al. teach that it is likely that this threshold will change depending on the disease as well as the experiment (2<sup>nd</sup> paragraph of left column of page 412). Hu et al. states clearly: "It is not uncommon to see expression changes in microarray experiments as small as 2-fold reported in the literature. Even when these expression changes are statistically significant, it is not always clear if they are biologically meaningful" (bottom of right column of page 411). Hu et al. further states: "in any microarray experiment, thousands of genes may demonstrate statistically significant expression changes, but only a fraction of these may be relevant to the study" (1<sup>st</sup> paragraph of left column of page 405). In addition, Hu et al. comprehensively summarized and estimated the relative strengths of all human gene-disease relationships in Medline, and analyzed a microarray expression dataset comparing breast cancer and normal breast tissue in the context of existing knowledge (see, e.g., Abstract of Hu et al.). While it is true that "relationships established by frequency of co-citation do not necessarily represent a true biological link", as Hu et al. stated, "it is strong evidence to support a true relationship" (1<sup>st</sup> paragraph of right column of page 411). Further, while some functional molecules are not included in the analysis, a sample size of 2286 genes is sufficient to validate the author's conclusion. The purpose of a statistical analysis is to predict the property or behavior of the overall population based upon analysis of a sample of the population. In

Art Unit: 1647

view of the limited disclosure in the instant case, lack of disclosure of the “fold amplification” that was used to determine whether a higher expression was significant, lack of the statistical analysis, and lack of establishment of a correlative link between gene expression and protein level or a causal link between mRNA expression and esophageal tumor, the teachings of Hu et al. support the PTO’s position that further research is needed to reasonably identify or confirm a specific and substantial utility for the instantly claimed polypeptide of SEQ ID NO: 136.

Appellants argue that the lack of a known role for PRO1926 polypeptide in cancer does not prevent its use as a diagnostic tool for cancer (see Page 18 of the Brief). Although, the utility is credible and specific it is not substantial. Appellant quotes from M.P.E.P. § 2107 regarding the requirement for a substantial asserted utility. Appellant argues that they have demonstrated at least one reasonable use for the PRO1926 polypeptide as a diagnostic marker for cancer. It is asserted that the mere identification of altered expression in tumors is relevant to diagnosis of tumors, and, therefore, provides an immediate benefit to the public. This has been fully considered but is not found to be persuasive. M.P.E.P. § 2107 I states:

A “substantial utility” defines a “real world” use. Utilities that require or constitute carrying out further research to identify or reasonably confirm a “real world” context of use are not substantial utilities.

In the instant case, the asserted utility that PRO1926 polypeptides are useful as diagnostic markers for cancer is not substantial in that further research is required to reasonably confirm a real world context of use. In order for PRO1926 polypeptide to be useful as a cancer diagnostic, there must be a detectable change in the amount or form

Art Unit: 1647

of PRO1926 polypeptide between cancerous and healthy tissue. In the instant case, the evidence of record indicates that (1) cDNA is more highly expressed in normal esophagus tissue compared to esophageal tumor and (2) increased mRNA levels do not reliably correlate with increased polypeptide levels (Hu et al., Chen et al., Gygi et al. and Haynes et al.). In view of this, the skilled artisan would have viewed the cDNA amplification results as preliminary with respect to the utility of the encoded polypeptides, and would have had to experiment further to reasonably confirm whether or not PRO1926 polypeptides (SEQ ID NO: 136) can be used as a cancer diagnostic agent.

Appellants contend that the data in Example 18 and the 1<sup>st</sup> Grimaldi declaration are therefore sufficient to establish the asserted utility, and that the Examiner has not rebutted the presumption of utility that the Appellants' application is afforded. Further Appellants contend that Mr. Grimaldi is an expert in the field who conducted or supervised the experiments at issue and his declaration is based on personal knowledge of the relevant facts at issue. This has been fully considered but is not found to be persuasive. As discussed above, in assessing the weight to be given expert testimony, the examiner may properly consider, among other things, (1) the nature of the fact sought to be established, (2) the strength of any opposing evidence, (3) the interest of the expert in the outcome of the case, and (4) the presence or absence of factual support for the expert's opinion. (1) In the instant case, the nature of the fact sought to be established is whether or not cDNA amplification is predictive of increased protein levels. (2) It is important to note that the instant specification only discloses

cDNA amplification data for PRO1926 (i.e., data regarding amplification of PRO1926 mRNA), and does not disclose any information regarding PRO1926 polypeptide levels. Furthermore, there is strong opposing evidence showing that mRNA amplification is not predictive of protein levels in normal and cancerous tissues and, in turn, that increased mRNA levels are frequently not predictive of increased polypeptide levels. See, e.g., Hu et al., discussed *supra*. (3) Regarding the interest of the expert in the outcome of the case, it is noted that Mr. Grimaldi is named as one of the inventor and is employed by the assignee. (4) Finally, Mr. Grimaldi refers to facts; however, the data is not included in the declaration so that the examiner could not independently evaluate them. There is no protein data. In conclusion, the Examiner submits that based on consideration of the evidence as a whole, the rejection is proper.

Beginning at page 19 of the Brief, Appellants argue that the Haynes et al., Gygi et al., and Chen et al., do not refute Appellants assertion that a change in mRNA levels leads to a corresponding change in the level of the encoded protein. Contrary to Appellants assertion that Haynes et al. does not contradict the utility and enablement of the instant claims, Haynes et al. states that "These results suggest that even for a population of genes predicted to be relatively homogeneous with respect to protein half-life and gene expression, the protein levels cannot be accurately predicted from the level of the corresponding mRNA" (page 1863, 2<sup>nd</sup> paragraph). Appellants contend that Haynes et al. did not examine whether a change in transcript level for a particular gene led to a change in the level of expression of the corresponding protein. Haynes et al., had studied more than 80 polypeptides relatively homogeneous in half-life and

Art Unit: 1647

expression level found no strong correlation between polypeptide (steady state) and transcript levels. Appellants assert that Haynes et al. reported that they “found a general trend but no strong correlation between protein and transcript levels”. However, Appellants assert that inspection of Figure 1 shows clear correlation between the mRNA levels and protein levels measured. Further it is claimed that this correlation is confirmed by an inspection of the full-length research paper from which the data in Figure 1 were derived, (Gygi et al. Molecular and Cellular Biology, 1999, 1720-1730, a reference provided by the Appellants after final). Although Appellants assert that there is a strong correlation between mRNA expression and protein expression, Gygi et al. conclude that transcript levels provide little predictive value with respect to the extent of the protein expression (page 1730, last line). Furthermore, Gygi et al. clearly state that the correlation between mRNA and protein levels was insufficient to predict protein expression levels from quantitative mRNA data (see abstract). Appellants contend that Haynes and Gygi et al. looked at the static level of mRNA across many genes not changes in the level of expression for single gene. In response to Appellants argument that the references fail to show certain features of applicant’s invention, it is noted that the features upon which applicant relies (i.e., changes in message levels are correlated to protein levels) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See In re Van Geuns, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). While it is true that Haynes and Gygi references discussed the steady state levels, they

Art Unit: 1647

were relied upon by the Examiner to illustrate the point that in general there is no correlation between mRNA expression and the polypeptide expression.

In addition, Appellants have failed to establish that there exists a correlation between the message levels and the protein levels of PRO1926 either in steady state or in a dynamic changing environment. Appellant appear to argue that Haynes teaches that there was a general trend but no strong correlation, between protein and transcript levels and there is a positive correlation between mRNA and protein among most of the 80 yeast proteins studied. On the another hand, Appellant argues that the Haynes et al. did not compare mRNA expression levels and protein levels in the same yeast cells and thus the analysis by Haynes et al. is not applicable to the present application.

Appellants' argument has been fully considered, but is not deemed to be persuasive for the following reasons. First, Appellant ignores the overall teachings of Haynes et al. At 2<sup>nd</sup> paragraph of left column of page 1863, Haynes et al. clearly states, "For some genes studied, equivalent mRNA transcript level translated into protein abundances which varied by more than 50-fold. Similarly, equivalent steady state protein expression levels were maintained by transcript levels varying by as much as 40-fold". Clearly, Appellant's argument that a positive correlation exists between mRNA and protein is not true. Moreover, Haynes et al. conclude "The multi-level control of protein synthesis and degradation in cells means that only the direct analysis of mature protein products can reveal their correct identities, their relevant state of modification and/or association and their amounts" (bottom of left column of page 1870). Accordingly, the limited disclosure in the instant case does not meet the legal standard for a specific and substantial utility.

Furthermore, Appellant's arguments that Haynes et al. did not compare mRNA expression levels and protein levels in the same yeast cells are invalid because Haynes et al. clearly states: "we have determined the correlation of expression at the mRNA and protein levels for a population of selected genes in the yeast *Saccharomyces cerevisiae* growing at mid-log phase (the 2<sup>nd</sup> paragraph of left column of page 1863).

At the top of page 21 of the Brief, Appellants assert that Chen et al. (2002, *Molecular and Cellular Proteomics* 1:304-313) is not relevant to Appellant's assertion that changes in the level of mRNA lead to changes in the level of the encoded polypeptide. Further on page 21 of the Brief, Appellants argue that Chen et al. "read in its entirety" provides scant evidence to counter Appellants' asserted utility because portions of reference support Appellants' assertions, and the remaining portions provide little insight into the relationship between changes in mRNA levels and changes in the corresponding protein levels for mRNA that is differentially expressed in tumor cells relative to normal cells. Appellants' argument has been fully considered, but is not deemed to be persuasive for the following reasons. Chen et al. compared mRNA and protein expression for a cohort of genes in the same lung adenocarcinomas. Only 17% of 165 protein spots or 21% (21 of 98) of the genes had a significant correlation between protein and mRNA expression levels. That is only a subset of the protein exhibited a significant correlation with mRNA abundance. Chen et al. clearly state that "the use of mRNA expression patterns by themselves, however, is insufficient for understanding the expression of protein products" (p. 304) and "it is not possible to predict overall protein expression levels based on average mRNA abundance in lung cancer samples" (pp.



311-312). Chen et al. summarize their findings by stating, “using a quantitative analysis of mRNA and protein expression within the same lung adenocarcinomas, we showed that only a subset of the proteins exhibited a significant correlation with mRNA abundances” (abstract). Furthermore, as with the Haynes et al. reference above, Appellants are challenging portions of the reference selectively, including the assertion that the reference does not address the change in the mRNA levels and changes in protein levels, Appellants are again arguing a limitation that is not present in the claims. The Chen reference taken as a whole clearly argues against Appellants position that there is a correlation between mRNA and protein expression. Since, the instant specification does not provide additional information regarding whether or not PRO1926 polypeptide is more highly expressed in normal esophagus compared esophageal tumor, and thus the skilled artisan would need to perform additional experiments to reasonably confirm such. Therefore, the asserted utility for the claimed polypeptides is not in currently available form, the asserted utility is not substantial.

Appellants on page 24 of the Brief assert that the Examiner has failed to establish a *prima facie* case that one of skilled in the art would doubt Appellants' asserted utility. It is asserted by the Appellant that the Examiner has relied on essentially two arguments in rejecting the pending claims for lack of utility. First, it is claimed that the examiner has questioned the sufficiency, reliability and significance of the data reported in Example 18 as well as the supporting first Grimaldi declaration. Secondly, it is asserted that the Examiner relied on the references of Haynes et al. Gygi et al. and Chen et al. to support the assertion that the polypeptide levels cannot be

Art Unit: 1647

accurately predicted from mRNA levels. However, the Examiner in rejecting the pending claims for lack of utility, noted that PCR amplification as described in Example 18, merely measures the mRNA level; it does not measure the over-expression of the polypeptide of SEQ ID NO: 136. There is insufficient information or experimental data presented on whether the polypeptide of the present invention can serve as a reliable diagnostic marker for esophageal tumor and there is no statistical analysis of the expression data (mRNA). Moreover, the assay does not establish a causative link between the polypeptide of the present invention and esophageal tumor. Without such critical information, one skilled in the art would not be able to use the molecule of the present invention as a diagnostic marker or as a therapeutic target for treatment of esophageal tumor without undue experimentation. Accordingly, the results obtained based upon the assay described in Example 18 only serve as the beginning point for further research on the biological functions or physiological significance of the antibody that binds to the polypeptide of SEQ ID NO: 136 or polypeptide of SEQ ID NO: 136 or the nucleic acid encoding the polypeptide, and does not provide a specific and substantial utility for the present invention. In addition, the Examiner has cited Hu et al. that cautions researchers against drawing conclusions based on small changes in transcript expression levels between normal and cancerous tissue. Furthermore, the Examiner has also cited Haynes et al. Gygi et al., and Chen et al. references to teach that mRNA levels do not in general predict protein levels in general. In view of the totality of the evidence, the rejections for lack of utility and enablement are proper.

Appellants on page 25 of the Brief indicate that they have provided sufficient rebuttal evidence (including the first Grimaldi declaration) of utility and also claim that they have established that the gene encoding the PRO1926 polypeptide is differentially expressed in certain cancers (page 26 of the brief). Contrary to Appellants assertion that the Examiner has not provided any evidence or reasoning to challenge the reliability and significance of the data in Example 18 which reports that the mRNA for PRO1926 is more highly expressed in normal esophagus tissue compared to esophageal tumor respectively, the Examiner has provided published prior art that (1) cautions researchers against drawing conclusions based on small changes in transcript expression levels between normal and cancerous tissue and (2) references that teach that mRNA levels do not in general predict protein levels in general. Appellants contend that Grimaldi declaration establishes that it is the opinion of an expert in the field who has personal knowledge of the facts surrounding Example 18 that there is at least a two-fold difference in mRNA for PRO1926 between the tumor tissue and the counterpart normal tissue, and that the PRO1926 genes, polypeptides are useful for differentiating tumor tissue from normal tissue. This has been fully considered but not found to be persuasive because this appears to be declarant's opinion, and is not supported by fact or evidence (See Office Action 6/22/2005, page 7 and 10). There is no description in the specification that would indicate a correlation with higher or lower expression levels of the message to the PRO1926 polypeptide. It remains that; there is no information on the record as to whether the claimed protein is expressed at all in the esophageal tissue, cancerous or otherwise. The specification does not disclose any special feature or

prognosis, of esophageal tumor indicating differential expression to distinguish tumor tissue from normal tissue. It is left to the skilled artisan to determine the significance (if any) of such difference. Such constitutes the type of further research required to bestow a substantial utility on the claimed invention, that of the PRO1926 polypeptide.

Appellants contend on page 26 of the Brief that it is well established in the art that in most cases a change in the level of mRNA for a particular protein leads to corresponding change in the level of the encoded protein. Appellants assert that the second declaration provided by Mr. Grimaldi supports this assertion. Citing paragraph 5, of the declaration Appellants contend that "the detection of increased mRNA expression is expected to result in increased polypeptide expression, and detection of decreased mRNA expression is expected to result in decreased polypeptide expression. At paragraph 4 of the second Grimaldi declaration, the declarant discusses mutations of Her2/Neu (c-erbB2), and chromosomal translocations that are known to be associated with cancer, and states that "If the chromosomal aberration results in the aberrant expression of a mRNA and the corresponding gene product (the polypeptide) as they do in the aforementioned cases, then the gene product is a promising target for cancer therapy, for example, by the therapeutic antibody approach." This argument has been fully considered but is not deemed persuasive because it evinces that the instant specification provides a mere invitation to experiment, and not a readily available utility. The PRO1926 gene, unlike Her2/Neu, has *not* been associated with tumor formation or the development of cancer, nor has it been shown to be predictive of such. Similarly, unlike t (5;14), no translocation of PRO1926 gene is known to occur. All that the

Art Unit: 1647

specification demonstrates is that the PRO1926 nucleic acid was more highly expressed in normal esophagus tissue compared to esophageal tumor tissues. No mutation or translocation of PRO1926 has been associated with esophageal cancers. In the absence of any of the above information, all that the specification does is present evidence that the cDNA encoding PRO1926 polypeptide is amplified in an unknown number of samples, and invite the artisan to determine the rest of the story. Such is insufficient to meet the requirements of 35 U.S.C. § 101 for the claimed polypeptides.

In addition, Appellants assert that the declaration submitted by Dr. Polakis asserts that, "it remains a central dogma in molecular biology that increased mRNA levels are predictive of corresponding increased levels of the encoded protein (at paragraph 6 of the declaration). Beginning at page 27 of the Brief (see also pages 29 and 34 of the Brief), Appellant argues that it is more likely than not for increased mRNA levels to predict increased protein levels. Appellant presents a declaration by Dr. Polakis under 37 CFR 1.132 as evidence that mRNA expression correlates well with protein levels in general. In the declaration, Dr. Polakis states that a primary focus of the tumor antigen project is to identify tumor cell markers useful as targets for diagnosis and treatment of cancer in humans. Dr. Polakis states that a variety of scientific techniques, including microarray analysis, have been used for detecting and studying differential gene expression in human tumor cells relative to normal cells at genomic DNA, mRNA, and protein levels. Dr. Polakis states that approximately 200 genes transcripts are present in human tumor cells at significantly higher levels than in corresponding normal human cells. Dr. Polakis states that antibodies to about 30 of the tumor antigen proteins

Art Unit: 1647

have been developed and used to quantitatively determine the level of production of these tumor antigen proteins in both human cancer cells and corresponding normal cells. Dr. Polakis states approximately 80% of samples show correlation between increased mRNA levels and changes in the level of protein expressed from that mRNA. Dr. Polakis states that it remains a central dogma in molecular biology that increased RNA levels are predictive of corresponding increased levels of the encoded protein. Dr. Polakis characterizes the reports of instances where such a correlation does not exist as exceptions to the rule. The declaration of Dr. Polakis is insufficient to overcome the rejection of claims 6-8 and 11-17 under 35 U.S.C. §101 and Appellant's argument is not deemed to be persuasive for the following reasons.

First of all, it is important to note that Dr. Polakis clearly states that a variety of scientific techniques, including microarray analysis, have been used for detecting and studying differential gene expression in human tumor cells relative to normal cells at genomic DNA, mRNA, and protein levels. Dr. Polakis does not state that tumor versus normal differential tissue expression using PCR amplification analysis alone can establish the use of a polypeptide as a diagnostic marker for a specific tumor. Secondly, Dr. Polakis states approximately 80% of the samples show correlation between increased mRNA levels and changes in the level of protein expressed from that mRNA. However, Dr. Polakis does not state whether the increase in protein level was significant enough to be meaningful as being a diagnostic marker for esophageal tumors. Thirdly, although, Dr. Polakis states that approximately 200 genes transcripts that are present in human tumor cells at significantly higher levels than in corresponding normal human

cells, Dr. Polakis does not state that how many proteins encoded by the 200 genes are expressed at significantly higher levels than in corresponding normal human cells. Dr. Polakis states that antibodies to about 30 of the tumor antigen proteins have been developed and used to quantitatively determine the level of production of these tumor antigen proteins in both human cancer cells and corresponding normal cells. Dr. Polakis does not state that the 30 "tumor antigen proteins" are expressed at significantly higher levels in human tumor cells than in corresponding normal human cells. Moreover, the declaration does not provide data such that the Examiner can independently analyze and draw conclusions. Only Dr. Polakis' conclusions are provided in the declaration. There is no evidentiary support to Dr. Polakis' statement that it remains a central dogma in molecular biology that increased mRNA levels are predictive of corresponding increased levels of the encoding polypeptide. In fact, the art teaches the protein levels cannot be accurately predicted from the level of the corresponding mRNA transcript (Haynes et al., *Electrophoresis*, 19:1862-1871, 1998; see, left column of page 1863; Figure 1). While the absolute certainty is not the legal standard for utility, a specific and substantial utility in reasonably confirmed and practical form is required for the claimed invention.

Appellants, along with the Grimaldi and Polakis declarations, also provide teachings from Molecular Biology of the Cell by Bruce Alberts and Genes VI (1997) by Ben Lewin, to support their assertion that there is a correlation between increased gene expression and increased protein expression (pages: 27-29 of the Brief). Appellants also refer to additional articles by Zhigang et al., and Meric et al. as providing evidence

Art Unit: 1647

that gene amplification generally results in elevated levels of the encoded polypeptide. Zhigang et al. describe a specific example of the expression of prostate stem cell antigen (PSCA) protein and mRNA to validate it as potential molecular target for diagnosis and treatment of human prostate cancer. It is asserted that the data shows “a high degree of correlation between PSCA protein and mRNA expression”. Further Meric et al. states “the fundamental principle of molecular therapeutics in cancer is to exploit the differences in gene expression between cancer cells and normal cells. Meric et al. also teaches that most efforts have concentrated on identifying differences in gene expression at the level of mRNA, which can be attributable to either DNA amplification or to differences in transcription. Although, Appellants contend that the regulation is primarily at the transcriptional level (based on teachings found in Molecular Biology of the Cell), the prior art references discussed above teach that gene expression is quite complicated and is regulated at the level of mRNA transcription, mRNA stability, mRNA translation and protein stability. In addition, unlike the instant invention, Zhigang et al. provide immunohistochemical analysis and mRNA hybridization to correlate the mRNA expression with the protein for a known prostate stem cell antigen (PSCA). Unlike the instant PRO1926 polypeptide, PSCA is well characterized and is a cell surface antigen that is predominantly prostate specific (see page 2). Further reading of Meric et al. seems to teach away from Appellants’ claim that there is a direct correlation between increased mRNA levels and the level of expression of the encoded protein. For example, the reference discloses that variations in mRNA sequences increase or decrease translational efficiency as found in BRCA1 (see pages 973-974). In addition,



Art Unit: 1647

advances in technology, allowing comparisons of message and protein using proteomics, show a lack of correlation, as is evidenced by Haynes et al., Chen et al., and Gygi et al.

Appellants assert that declarations of Grimaldi and Polakis, the accompanying references, and the excerpts and references discussed establish that the accepted understanding in the art is that there is a reasonable correlation between changes in gene expression and changes in the in the level of the encoded protein. It is the contention of the Appellants that substantial amount of evidence supporting their position has been provided and criticizes the Examiner for not providing adequate references to support the lack of utility. Appellant's argument has been fully considered, but is not deemed to be persuasive for the reasons set forth immediately above. Therefore, considered as a whole, the overwhelming amount of evidence it is believed that the rejection should be sustained.

At the p. 30 of the Brief, Appellant argues that the asserted utility for PRO1926 as a cancer diagnostic is specific. The examiner agrees.

Appellants on pages 31-32 of the Brief argue that the Examiners response to 1<sup>st</sup> Grimaldi declaration is not adequate and remind the Examiner that the declaration of Mr. Grimaldi is based on personal knowledge of the relevant facts at issue. Further it is asserted "[o]ffice personnel must accept an opinion from a qualified expert that is based upon relevant facts whose accuracy is not being question." In addition, it is argued that declarations relating to issues of fact should not be summarily dismissed as "opinions" without adequate explanation of how the declaration fails to rebut the Examiners'

position. Appellants maintain that the procedures used to detect differences in expression levels were sufficiently sensitive to detect two-fold differences (see page 32 of the Brief)). Appellant further argue that the Examiner has not supplied any reasons or evidence to question the accuracy of the facts upon which Mr. Grimaldi based his opinions. Contrary to Appellants assertions that the Examiner has not supplied any reason or evidence in support of his position, the Examiner offered evidence from the literature which cautions researchers against drawing conclusions based on small changes in transcript expression levels between normal and cancerous tissue (see Hu et al., pages 5 and 14 of the Office Action dated 6/22/2005). In addition and as indicated above, Mr. Grimaldi has an interest in the case, since he is employed by the assignee. Finally, while Mr. Grimaldi bases his findings with reference to facts, the facts are not independently provided for the examiner to draw independent conclusions. For example, it is not clear if any of the tumors were from esophageal tissue etc., or how highly amplified the genes were that correlated with polypeptide overexpression.

Appellants on pages 32-34 of the Brief argue that the Examiners arguments to 2<sup>nd</sup> Grimaldi declaration fail to establish that one of skill in the art would doubt Appellants' asserted utility. The Examiner in the Office Action mailed 6/22/2005 (page 9) indicated that the PRO1926 gene, unlike Her2/Neu, has *not* been associated with tumor formation or the development of cancer, nor has it been shown to be predictive of such. Similarly, unlike t (5;14), no translocation of PRO1926 gene is known to occur. All that the specification demonstrates is that the PRO1926 nucleic acid (mRNA) was more highly expressed in normal esophagus tissue compared to esophageal tumor tissues.

No mutation or translocation of PRO1926 has been associated with esophageal cancer. In the absence of any of the above information, all that the specification does is present evidence that the cDNA encoding PRO1926 polypeptide is amplified in an unknown number of samples, and invite the artisan to determine the rest of the story. Contrary to Appellants assertion that the Examiner fails to establish how the "absence of any of the above information" is relevant to the asserted utility by supplying evidence or reasoning to support his assertion, the Examiner indeed has provided the reasoning that PRO1926 gene is not associated with tumor formation and no translocation has been associated with PRO1926 unlike Her2/Neu or t(5;14) discussed above and in the Grimaldi declaration. Even if the differential message expression can be used in the diagnosis of cancer, the lack of a nexus between the differential message expression and polypeptide of PRO1926, make the rejections for lack of utility proper. Furthermore, Appellants have cited example 12 from the utility guidelines for consideration (page 34 in the brief). This has been fully considered but the fact patterns are different between example 12 and the instant invention. In example 12, it is stated that the "specification discloses that receptor A is present on the cell membranes of melanoma cells but not on the cell membranes of normal skin cells. However, the instant disclosure does not provide any such disclosure. Appellants also provide several patents in which apparently analogous fact pattern exists. As indicated by the Appellants themselves "... actions taken in other applications are not binding on the PTO with respect to the present application." Appellants also argue that they only relied on paragraph 5 of the declaration for their support. This is not found to be persuasive because the Examiner

considered the entire declaration in evaluating its relevance/support to the instant invention.

On page 36 of the Brief Appellants also state that the Examiner has taken out of context Mr. Grimaldi's assertion in the 1<sup>st</sup> declaration that "additional studies can then be conducted if further information is desired". On the contrary, the Examiner did not take this statement out of context. It was assumed that if there was differential expression of the message that was detected further studies could be conducted to determine nexus to the protein.

From p. 34 to p. 36 of the Brief, Appellant comments upon the examiner's evaluation of the Polakis declaration. Specifically, Appellant argues that the Polakis declaration was submitted to support the position that there is a correlation between mRNA and polypeptide levels. Appellant urges that the opinions in the Polakis declaration are all based on factual findings. Appellant cites case law concerning the examiner's requirement to consider all of the evidence of record anew, and that opinion evidence must be considered. Appellant also points to the utility guidelines as directing the examiner to accept an opinion from an expert. Appellant points to the statement in the Polakis declaration that it is Dr. Polakis' considered scientific opinion that for human genes, an increased level of mRNA in a tumor cell relative to a normal cell typically correlates with a similar increase in abundance of the encoded protein in the tumor cell relative to the normal cell. Appellant concludes that the fact-based conclusions of Dr. Polakis would be considered reasonable and accurate by the skilled artisan. This has been fully considered but is not found to be persuasive. As discussed above, in

assessing the weight to be given expert testimony, the examiner may properly consider, among other things, (1) the nature of the fact sought to be established, (2) the strength of any opposing evidence, (3) the interest of the expert in the outcome of the case, and (4) the presence or absence of factual support for the expert's opinion. In the instant case, the nature of the fact sought to be established (1) is whether or not increased mRNA levels are predictive of increased polypeptide levels. The art provides strong evidence (2) that increased mRNA levels do not correlate with increased protein levels in both healthy and cancerous tissues. See Haynes et al., Gygi et al., Hu et al., and Chen et al. Additionally, Dr. Polakis has an interest in the case since he is employed by the assignee (3). Finally, while Dr. Polakis bases his findings with reference to facts, the facts are not independently provided for the examiner to draw independent conclusions (4). For example, it is not clear if any of the tumors were from esophagus, or how highly amplified the genes were that correlated with polypeptide overexpression. Based on the totality of the evidence, it is maintained that one skilled in the art would view the instant differential mRNA expression data as merely preliminary with regard to whether or not protein levels of PRO1926 are differentially expressed in esophageal tumors. Further research would have to be done in order to determine if PRO1926 protein are differentially expressed and, if so, whether or not the differential expression is significant enough to reasonably confirm the usefulness of PRO1926 protein as an esophageal cancer marker. Thus, the claimed invention does not provide products or services in "currently available" to the public, and the asserted utility is not substantial. Again, Appellants emphasize that the data in Example 18 are for gene expression, not

Art Unit: 1647

gene amplification. This has been previously conceded by the Examiner, and does not affect the position of the Examiner in challenging the asserted utility of the instant invention or the Polakis declaration. Further, contrary to Appellants assertion on pages 37-38, the Examiner maintains that there is no nexus between the mRNA levels of the instant invention and polypeptide of PRO1926.

Appellants on pages 37 of the Brief respond to Examiners arguments with respect to Meric et al. reference in the Office Action dated 6/22/2005. This is not found to be persuasive (see page 10-11 of the Office Action). Appellants acknowledge that gene expression is regulated at numerous levels. However, they contend that the supporting references and declarations supplied make clear, regulation of mRNA levels is the predominant mechanism of control for the majority of genes. Appellants point to Meric et al. statement that "the fundamental principle of molecular therapeutics in cancer is to exploit the differences in gene expression between cancer cells and normal cells. Meric et al. also teaches that most efforts have concentrated on identifying differences in gene expression at the level of mRNA, which can be attributable to either DNA amplification or to differences in transcription. Although, Appellants contend that the regulation is primarily at the transcriptional level (based on teachings found in Molecular Biology of the Cell), the prior art references discussed above teach that gene expression is quite complicated and is regulated at the level of mRNA transcription, mRNA stability, mRNA translation and protein stability (also Meric et al 1<sup>st</sup> paragraph of page 971). Appellants also argue that the only reason mRNA is of any interest in studying the mechanism of cancer formation and growth is because mRNA encodes

protein. It is further asserted "if there were no general correlation between differences in mRNA and differences in protein, there would be no reason to study changes in mRNA". Thus Appellants contend that contrary to the Examiner's position, Meric et al. supports the position that, in general, differential expression of mRNA correlates with differential expression of the encoded polypeptide. This is not found to be persuasive because, further reading of Meric et al. seems to teach away from Appellants' claim that there is a direct correlation between increased mRNA levels and the level of expression of the encoded protein. For example, the reference discloses that variations in mRNA sequences increase or decrease translational efficiency as found in BRCA1 (see pages 973-974). ). In addition, advances in technology, allowing comparisons of message and protein using proteomics, show a lack of correlation, as is evidenced by Haynes et al., Chen et al., and Gygi et al.

Appellants argue extensively in pages 38-44 of the brief that courts have held that the utility requirement was satisfied in similar cases. Finally on page 44 of the Brief, Appellant concludes by stating that the instant specification discloses a specific, credible and substantial utility for the PRO1926 polypeptide as a diagnostic marker for esophageal tumors. The Examiner believes that the rejections should be sustained for the reasons set forth above.

## **II. Rejection of claims 6-8 and 11-17 under 35 USC § 112, 1<sup>st</sup> paragraph, enablement**

Claims 6-8 and 11-17 are also rejected under 35 U.S.C. 112, first paragraph.

Specifically, since the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

Appellant refers to the arguments and information presented in response to the rejection under 35 U.S.C. § 101 (see page 46 of the brief). Appellant submits that the PRO1926 polypeptides have utility in the diagnosis of cancer. However, the Examiner believes that since Appellant has not provided evidence to demonstrate that the PRO1926 polypeptide has a specific and substantial asserted utility or a well established utility, one skilled in the art would not know how to use the claimed invention.

In addition, even if the claimed invention is eventually deemed to have a credible, specific and substantial asserted utility or a well established utility, claims 14-17 would remain rejected under 35 U.S.C. § 112, first paragraph.

At pages 47-48 of the Brief, Appellant cites pertinent case law reviewing the legal standard of enablement. The Examiner takes no issue with Appellant's general comments regarding the legal standard for enablement.

At page 49 of the Brief, Appellant contends that the specification teaches how to make and use the claimed subject matter. Specifically polypeptides of SEQ ID NO: 136, fragments thereof, and the polypeptide encoded By ATCC deposit 203547, and the polypeptides which are at least 95% identical to those polypeptides or fragments and which can be used to make antibodies that specifically detect PRO1926 in skin tissue. At pages 49-52 of the Brief, Appellant argues that the specification discloses how to



Art Unit: 1647

make the claimed polypeptides and its variants. It is also asserted it is well known in the art that to make the variants. Further it is asserted that the methods using the antibodies in diagnostic assays are well known in the art and are disclosed in the specification.

Appellants also assert that because the specification teaches how to make and use the claimed subject matter, the Office must take as being in compliance with the enablement requirement. Appellants on page 50 of the Brief citing MPEP § 2164.04 argue that the initial burden to establish a reasonable basis to question the enablement with acceptable evidence or reasoning must be provided by the Examiner. Appellants also argue that that Examiner's arguments fail to establish a reasonable basis to question the enablement. The Examiner did provide the reasons to question the claimed invention on pages 9-11 of the Office Action dated 1/11/2005 and pages 16-18 of the Office Action dated 6/22/2005. According to In re Bowen, 492 F.2d 859, 862-63, 181 USPQ 48, 51 (CCPA 1974), the minimal requirement is for the examiner to give reasons for the uncertainty of the enablement. The examiner concluded based on the lack of disclosure in the specification of the variants (with specific biological activities) contemplated by the Appellants, that the specification fails to teach how to make and use the claimed invention without undue experimentation, or that the scope of any enablement provided to one skilled in the art is not commensurate with the scope of protection sought by the claims.

Appellants also discuss the Wands factors on page 51 of the Brief. Appellant's arguments have been fully considered but are not found to be persuasive.

The broad-brush discussion of making and screening for variants does not constitute a disclosure of a representative number of members. No such variants were made or shown to have activity. Only the PRO1926 polypeptide of SEQ ID NO: 136 is disclosed. According to MPEP § 2164.06, "the guidance and ease in carrying out an assay to achieve the claimed objectives may be an issue to be considered in determining the quantity of experimentation needed. For example, if a very difficult and time consuming assay is needed to identify a compound within the scope of the claim, then this great quantity of experimentation should be considered in the overall analysis". The specification's general discussion of making and screening for variants constitutes an invitation to experiment by trial and error. Such trial and error experimentation is considered undue. Certain positions in the polypeptide sequence are critical to the protein's structure/function relationship, e.g., such as various sites or regions directly involved in binding, activity, and in providing the correct three-dimensional spatial orientation of binding and active sites. Even if an active or binding site were identified in the specification, they may not be sufficient, as the ordinary artisan would immediately recognize that an active or binding site must assume the proper three-dimensional configuration to be active, which conformation is dependent upon surrounding residues; therefore substitution of non-essential residues can often destroy activity. The art recognizes that function cannot be predicted from structure alone. However, Appellant has provided little or no guidance beyond the mere presentation of sequence data to enable one of ordinary skill in the art to determine, without undue experimentation, the positions in the PRO1926 protein which are tolerant to change (e.g. such as by amino

Art Unit: 1647

acid substitutions or deletions), and the nature and extent of changes that can be made in these positions. A large quantity of experimentation would be required by the skilled artisan to generate the infinite number of derivatives recited in the claims and screen the same for activity. As was found in Ex parte Hitzeman, 9 USPQ2d 1821 (BPAI 1987), a single embodiment may provide broad enablement in cases involving predictable factors such as mechanical or electrical elements, but more will be required in cases that involve unpredictable factors such as most chemical reactions and physiological activity. See also In re Fisher, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970); Amgen Inc. v. Chugai Pharmaceutical Co. Ltd., 927 F.2d 1200, 1212, 18 USPQ2d 1016, 1026 (Fed. Cir.), cert. denied, 502 U.S. 856 (1991).

Thus, the skilled artisan would not be able to determine, without undue experimentation, the structural conformation and function of PRO1926 variants based upon linear amino acid sequences only. One skilled in the art would also not be able to determine, without undue experimentation, the positions in the PRO1926 protein, which are tolerant to change (e.g. such as by amino acid substitutions or deletions), and the nature and extent of changes that can be made in these positions. The ordinary artisan would immediately recognize that an active or binding site must assume the proper three-dimensional configuration to be active, which conformation is dependent upon surrounding residues; therefore substitution of non-essential residues can often destroy activity.

Appellants have provided little or no guidance beyond the mere presentation of sequence data to enable one of ordinary skill in the art to determine, without undue

Art Unit: 1647

experimentation, the positions in the protein which are tolerant to change (e.g. such as by amino acid substitutions or deletions), and the nature and extent of changes that can be made in these positions. Therefore, undue experimentation would be required of the skilled artisan to make and/or use the claimed invention in its full scope, because the skilled artisan would have no reasonable expectation of being able to make and use PRO1926 variants or fragments comprising the sequence for any purpose stated in the specification.

Contrary to Appellants assertions the Examiner did not make an attempt to argue that one of skill in the art would be unable to make the claimed polypeptides, as stated previously Office did provide the reasons to question the claimed invention on pages 9-11 of the Office Action dated 1/11/2005 and pages 16-18 of the Office Action dated 6/22/2005. In addition, Appellants citing MPEP § 2164.05 argue that the evidence provided by applicant need not be conclusive but merely convincing to one skilled in the art (see page 48 of the Brief). However, Appellants have not provided any convincing evidence to indicate that a polypeptide or fragment of SEQ ID NO: 136 with at least 95% identity can be used to generate an antibody which can be used to specifically detect the polypeptide of SEQ ID NO: 136 in stomach or lung tissue. Claims 14-17 recite the limitation "wherein said isolated polypeptide or a fragment thereof can be used to generate an antibody which can be used to specifically detect the polypeptide of SEQ ID NO: 136 in esophageal tissue". These claims encompass any and all antigenically cross-reactive polypeptides possessing the recited percent identity, regardless of their biological activity. To obtain a valid patent, a patent application must

be filed that contains a full and clear disclosure of the invention in the manner prescribed by 35 U.S.C. 112, first paragraph. The requirement for an adequate disclosure ensures that the public receives something in return for the exclusionary rights that are granted to the inventor by a patent. If mere antigenic cross-reactivity were the test for enablement under § 112, Applicants could obtain patent rights that may confer power to block off whole areas of scientific development related to the biologic activity of the polypeptide, for which Applicants have not provided any disclosure. It is entirely unclear why the disclosure of a single polypeptide, i.e., PRO1926 (SEQ ID NO: 136), which is ideally suited to the making of antibodies to itself, would enable any and all antigenically cross-reactive polypeptides possessing the recited percent identity and possessing unknown and undisclosed biologic activities, when the specification provides no disclosure of any biological activity. Therefore, the scope of enablement provided to the skilled artisan by the disclosure is not commensurate with the scope of protection sought by the claims.

Although Appellant need not actually have reduced the invention to practice prior to filing the application, the lack of a working example is only one factor to be considered, especially in a case involving an unpredictable art (MPEP § 2164.02). Certain positions in the polypeptide sequence are critical to the protein's structure/function relationship, e.g., such as various sites or regions directly involved in binding, activity, and in providing the correct three-dimensional spatial orientation of binding and active sites. However, Appellant has provided little or no guidance beyond the mere presentation of sequence data to enable one of ordinary skill in the art to

determine, without undue experimentation, the positions in the PRO1926 protein which are tolerant to change (e.g. such as by amino acid substitutions or deletions), and the nature and extent of changes that can be made in these positions. A large quantity of experimentation would be required by the skilled artisan to generate the infinite number of derivatives recited in the claims and screen the same for activity. As discussed above, as was found in Ex parte Hitzeman, 9 USPQ2d 1821 (BPAI 1987), a single embodiment may provide broad enablement in cases involving predictable factors such as mechanical or electrical elements, but more will be required in cases that involve unpredictable factors such as most chemical reactions and physiological activity. See also In re Fisher, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970); Amgen Inc. v. Chugai Pharmaceutical Co. Ltd., 927 F.2d 1200, 1212, 18 USPQ2d 1016, 1026 (Fed. Cir.), cert. denied, 502 U.S. 856 (1991). Additionally, the broad-brush discussion of making and screening for variants does not constitute a disclosure of a representative number of members. No such variants were made or shown to have activity. Only the PRO1926 polypeptide of SEQ ID NO: 136 is disclosed. According to MPEP § 2164.06, “the guidance and ease in carrying out an assay to achieve the claimed objectives may be an issue to be considered in determining the quantity of experimentation needed. For example, if a very difficult and time consuming assay is needed to identify a compound within the scope of the claim, then this great quantity of experimentation should be considered in the overall analysis”. The specification’s general discussion of making and screening for variants constitutes an invitation to experiment by trial and error. Such trial and error experimentation is considered undue.

**III. Rejection of claims 14-17 under 35 USC § 112, 1<sup>st</sup> paragraph, written description**

It is noted that at page 55 of the Brief, Appellant cites pertinent case law reviewing the legal standard of written description. The Examiner takes no issue with Appellant's general comments regarding the legal standard for written description.

At page 58 of the Brief, Appellant submits that the instant specification evidences the actual reduction to practice of a full-length PRO1926 polypeptide of SEQ ID NO: 136. Thus, the genus of the polypeptides with at least 95% sequence identity to SEQ ID NO: 136, wherein said isolated polypeptide or fragment thereof can be used to generate an antibody which can be used to specifically detect the polypeptide of SEQ ID NO: 136 in esophageal tissue, would meet the requirement of 35 U.S.C. § 112, first paragraph as providing adequate written description. Appellant's arguments have been fully considered, but are not found to be persuasive. Specifically, Appellant has not described or shown possession of all polypeptides 95%, and 99% homologous to SEQ ID NO: 136, that still retain the function of SEQ ID NO: 136. Nor has Appellant described a representative number of species that have 95%, and 99% homology to SEQ ID NO: 136, such that it is clear that they were in possession of a genus of polypeptides functionally similar to SEQ ID NO: 136. Even one skilled in the art could not envision the detailed chemical structure of all or a significant number of encompassed PRO1926 polypeptides, and therefore, would not know how to make or use them. The specification of the instant application only teaches a PRO1926

polypeptide of SEQ ID NO: 136. However, the description of one PRO1926 polypeptide species (SEQ ID NO: 136), which is not a member of a known family of proteins, is not adequate written description of an entire genus of functionally equivalent polypeptides which incorporate all variants, fragments, and derivatives wherein the polypeptide or fragment thereof can be used to generate an antibody which can be used to specifically detect the polypeptide of SEQ ID NO: 136 in esophageal tissue.

Appellant argue that the Examiner has to present evidence why a person skilled in the art would not recognize in an applicant' s disclosure a description of the invention defined by the claims (see page 56 of the Brief). However, the courts have held that "we are of the opinion that the PTO has the initial burden of presenting evidence or reasons why persons skilled in the art would not recognize in the disclosure a description of the invention defined by the claims". In re Wertheim, 541 F.2d 257, 263, 191 USPQ 90, 97 (CCPA 1976). The Examiner has previously presented the reasons for inadequate written description in the Office Actions dated 1/11/05 and 6/22/05.

Appellants on page 54 of the Brief argue that the Examiner has failed to meet his initial burden of rebutting the presumption that the written description is adequate because nowhere in Final Office Action does the Examiner address his arguments to claims 14-17, and the arguments he made are either flawed, or do not apply to claims 14-17. Contrary to Appellants assertion that the Examiner did not address the lack of written description, the Examiner did address in the Office Actions of 1/11/05 (pages 11-13) and 6/22/05 (pages 16-18) the lack of written description support. Specifically it was noted that the Appellants did not describe or show possession of all peptides with 95-



Art Unit: 1647

99% sequence identity to SEQ ID NO: 136 that still retained the function of SEQ ID NO: 136. Further Appellants on page 58 of the Brief indicate that there is no substantial variation within species which fall within the scope of the claims, which require at least 95% or 99% amino acid sequence identity to the disclosed sequences related to SEQ ID NO: 136. However, adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of isolating it. The compound itself is required. See *Fiers v. Revel*, 25 USPQ2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1016. In addition, it is noted that MPEP 2163 [R-2] IA states that "The claimed invention as a whole may not be adequately described where an invention is described solely in terms of a method of its making coupled with its function and there is no described or art-recognized correlation or relationship between the structure of the invention and its function. A biomolecule sequence described only by a functional characteristic, without any known or disclosed correlation between that function and the structure of the sequence, normally is not a sufficient identifying characteristic for written description purposes, even when accompanied by a method of obtaining the claimed sequence".

At the middle of page 58 of the Brief, Appellant cites the Written Description Guidelines of the U.S. Patent Office and argues that in Example 14, the procedures for making variants were known in the art and the disclosure taught how to test for claimed catalytic activity. Thus, it is asserted that written description requirement was found to be satisfied for claims relating to polypeptides having 95% homology to a particular sequence and possessing a particular catalytic activity, even though the Applicants had

not made any variants. Appellants contend that similarly, the pending claims also have very high sequence homology to the disclosed sequences and must share the same expression pattern in certain tumors, or share an epitope sufficient to generate antibodies which specifically detect the polypeptide of SEQ ID NO: 136 in stomach or lung tissue samples. The fact pattern in the instant application is not analogous to Example 14 in the Revised Interim Written Description Guidelines. In Example 14 of the Guidelines, the claimed protein variants have a high percent sequence identity in combination with a specific functional limitation. In the example, the protein catalyzes the reaction of A→B and thus, methods of generating variants of the protein that have 95% identity and retain its activity are conventional in the art because deletions, substitutions, insertions, and additions of uncritical amino acid residues would not affect the enzyme activity. Moreover, such an enzyme would have a conserved structure that is responsible for the enzyme activity. Thus, it is likely predictable, based upon percent identity, which variant would share the same function. In contrast, in the instant case, polypeptide of PRO1926 has no utility and has no disclosed function. Furthermore, the specification and the claims do not disclose the identification of any particular portion of the PRO1926 structure that must be conserved in order to conserve the required function.

Even with high degree of homology and the alleged functional language in claims 14-17, the requirement for an adequate disclosure is not met, because the mere antigenic cross-reactivity were the test for written description under § 112, Applicants could obtain patent rights that may confer power to block off whole areas of scientific

development related to the biologic activity of the polypeptide, for which Applicants have not provided any disclosure. It is entirely unclear why the disclosure of a single polypeptide, i.e., PRO1926 (SEQ ID NO: 136), which is ideally suited to the making of antibodies to itself, would enable any and all antigenically cross-reactive polypeptides possessing the recited percent identity and possessing unknown and undisclosed biologic activities, when the specification provides no disclosure of any biological activity. It does not appear that the Appellant as of the filing date sought, he or she was in possession of the various homologous polypeptides recited in claims 14-17. Also note, for inventions in an unpredictable art, adequate written description of a genus which embraces widely variant species cannot be achieved by disclosing only one species within the genus. See, e.g., *University of California v. Eli Lilly and Co.* 43 USPQ2d 1398, 1406 (Fed. Circ. 1997).

Appellants also assert that the Examiner does not contest the written description support for any embodiment recited in dependent claims 16 and 17 (see page 59 of the Brief). This is not accurate. Claims 16 and 17 were included in the rejection for lack of written description support because these claims are dependent on claim 14, which lacks written description support (see page 16, of the Office Action dated 6/22/05).

Appellants also assert that by citing *In re Wallach* argue that the Examiner's premise that a large genus can not be adequately described a single species is simply wrong (see bottom of page 59-60). However, the fact pattern present in *In re Wallach* is different from instant invention. The claims were directed to polynucleotides sequences encoding the polypeptide. However, the court affirmed the Board's determination

(USPTO position) that the specification of the patent application did not provide an adequate written description of the pending claims. Appellants as in the instant application did not provide any evidence that there is any known or disclosed correlation between the combination of a partial structure of a protein and the protein's biological activity.

At page 61 the Brief, Appellant concludes this section by urging that the rejection of claims 14-17 under 35 U.S.C. § 112, first paragraph be reversed. The Examiner believes that the rejections should be sustained for the reasons set forth above.

**(IV) Rejection of claims 6-8, 11 and 14-15 35 U.S.C. § 102 (b)**

Claims 6-8, and 11-17 are rejected under 35 U.S.C. 102(b) as being anticipated by Valenzuela et al. (WO 00/55375, September 2000).

Appellants contend that they are entitled to an earlier priority date that is earlier than that of Valenzuel et al. based on the disclosure of SEQ ID NO: 129 and 130 and the data of Example 18 (differential tissue cDNA expression in tumor versus normal tissue), that was disclosed in PCT Application PCT/US00/23328, filed 8/24/2000 (see Brief page 62). However, Appellants have not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 120. Although, the previous patent application discloses the same polypeptide (SEQ ID NO: 136) sequence and polynucleotides (SEQ ID NO: 135) encoding the polypeptide as the instant specification, the disclosure is not enabling for the instant invention directed to the antibodies and because the disclosed function (differential cDNA) expression does not impart utility to

Art Unit: 1647

the instant invention directed to antibodies binding the polypeptide for the reasons set forth below and the previous Office Actions dated 1/11/05 and 6/22/05. Therefore, the filing date of 7 May 2002 is maintained as the priority date.

Valenzuel et al. (WO 00/55375) disclose an amino acid sequence that has 100% overall identity to SEQ ID NO: 136 of the instant invention. It meets the limitations of claims 6-8, 11, 14 and 15. It also describes fusion proteins with heterologous polypeptide such as maltose binding proteins (page 280, lines 25-30). In addition, the reference also teaches epitope tagging of the protein (page 280, lines 30-31), meeting the limitations of claims 12, 13, 16 and 17. Therefore, instant claims 6-8 and 11-17 remain rejected under 35 U.S.C. 102(b) as being anticipated over Valenzuela et al. (2000).

#### **(11) Related Proceeding(s) Appendix**

No decision rendered by a court or the Board is identified by the examiner in the Related Appeals and Interferences section of this examiner's answer.

For the above reasons, it is believed that the rejections should be sustained.

Art Unit: 1647

Respectfully submitted

Jegatheesan Seharaseyon, Ph.D

Examiner, Art Unit 1647


February 15, 2006



Conferees

Brenda Brumback.

SPE, Art Unit 1647



BRENDA BRUMBACK  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600

Janet Andres, Ph.D.

SPE, Art Unit 1649



JANET L. ANDRES  
SUPERVISORY PATENT EXAMINER